WO2005123103A1 - Topical compositions and methods for epithelial-related conditions - Google Patents

Topical compositions and methods for epithelial-related conditions Download PDF

Info

Publication number
WO2005123103A1
WO2005123103A1 PCT/US2005/020555 US2005020555W WO2005123103A1 WO 2005123103 A1 WO2005123103 A1 WO 2005123103A1 US 2005020555 W US2005020555 W US 2005020555W WO 2005123103 A1 WO2005123103 A1 WO 2005123103A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
group
composition
polyisoprenyl
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/020555
Other languages
English (en)
French (fr)
Inventor
Jeffry B. Stock
Joel Gordon
Maxwell Stock
Gregory Stock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signum Biosciences Inc
Original Assignee
Signum Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signum Biosciences Inc filed Critical Signum Biosciences Inc
Priority to CN2005800274693A priority Critical patent/CN101039689B/zh
Priority to CA2579605A priority patent/CA2579605C/en
Priority to ES05757465T priority patent/ES2420516T3/es
Priority to DK05757465.9T priority patent/DK1765376T3/da
Priority to BRPI0512021-7A priority patent/BRPI0512021A/pt
Priority to MXPA06014514A priority patent/MXPA06014514A/es
Priority to AU2005254035A priority patent/AU2005254035B2/en
Priority to RU2007101243/15A priority patent/RU2007101243A/ru
Priority to EP05757465.9A priority patent/EP1765376B1/en
Priority to JP2007527776A priority patent/JP4987715B2/ja
Publication of WO2005123103A1 publication Critical patent/WO2005123103A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/496—Triazoles or their condensed derivatives, e.g. benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • FIG 10. AFC reduces TPA-induced erythema
  • a "penetration enhancer” is an agent known to accelerate the delivery of a substance through the skin.
  • Suitable penetration enhancers usable in the present invention include, but are not limited to, dimethylsulfoxide (DMSO), dimethyl formamide (DMF), allantoin, urazole, N,N-dimethylacetamide (DMA), decylmethylsulfoxide (CioMSO), polyethylene glycol monolaurate (PEGML), propylene glycol (PG), propylene glycol monolaurate (PGML), glycerol monolaurate (GML), lecithin, the 1 -substituted azacycloheptan-2-ones, particularly l-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone R TM from Whitby Research Inco ⁇ orated, Richmond, Va.), alcohols, and the like.
  • the permeation enhancer may also be a vegetable oil. Such oils include, for example,
  • the water-ethanol mixtures are generally employed in a weight ratio from about 1:1 to about 20:1, preferably from about 3:1 to about 20:1, and most preferably from about 3:1 to about 10:1, respectively.
  • the pH value of the oral vehicle is generally from about 4 to about 7, and preferably from about 5 to about 6.5.
  • An oral topical vehicle having a pH value below about 4 is generally irritating to the oral cavity and an oral vehicle having a pH value greater than about 7 generally results in an unpleasant mouth feel.
  • anti-fungal agent means any of a group of chemical substances having the capacity to inhibit the growth of or to destroy fungi.
  • Anti-fungal agents include but are not limited to Amphotericin B, Candicidin, Dermostatin, Filipin, Fungichromin, Hachimycin, Hamycin, Lucensomycin, Mepartricin, Natamycin, Nystatin, Pecilocin, Perimycin, Azaserine, Griseofulvin, Oligomycins, Neomycin, Pyrrolnitrin, Siccanin, Tubercidin, Viridin, Butenafine, Naftifine, Terbinafine, Bifonazole, Butoconazole, Chlordantoin, Chlormidazole, Cloconazole, Clotrimazole, Econazole, Enilconazole, Fenticonazole, Flutrimazole, Isoconazole, Ketoconazole, Lanoconazole, Miconazole,
  • antioxidants that are usable in the context of the present invention include ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox R ), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutaminol
  • Hormone refers to natural substances produced by organs of the body that travel by blood to trigger activity in other locations or their synthetic analogs. Suitable hormones for use in the context of the present invention include, but are not limited to, calciferol (Vitamin D ) and its products, androgens, estrogens and progesterones.
  • Anti-dandruff agents refer to agents that reduce, eliminate or prevent a scurf from forming on skin, especially of the scalp, that comes off in small white or grayish scales.
  • a method of treating a medical, cosmetic and/or cosmeceutical condition associated with epithelial tissues is effected by topically applying, a pharmaceutically, cosmetically or cosmeceutically effective amount of the composition of the present invention as described above onto a surface.
  • Non limiting examples of epithelial surfaces onto which the compositions of the present invention can be applied topically include the lateral aspect of forearms, the lateral aspect of legs, elbows, feet, backhands, back, scalp, face, buttocks, the ear canal and any other skin surfaces, and any mucosal membrane described herein.
  • Topical application also includes applying the inventive compositions orally to the gingiva.
  • the surface is a wound surface.
  • topical application may include applying the inventive compositions to a non-epithelial surface such as the dermis.
  • the wound surface is an open wound surface.
  • an "open wound" is a physical trauma where the skin is lacerated, cut or punctured.
  • compositions of the invention also are administered to treat a skin disorder that is already present, such as dry cracked skin.
  • inventive compositions are administered to treat irritated skin, such as occurs with diaper rash.
  • Inflammation can result from a wide variety of non-limiting conditions. These conditions include, but are not limited to, a) dermatitis, including, but not limited to, atopic dermatitis, medicamentosa, contact dermatitis, sebonheic, nummular dermatitis, chronic dermatitis of hands and feet, generalized exfoliative stasis, and localized scratches; b) acne, including, but not limited to, acne vulgaris, nodulocystic acne, acne fulminans, steroid acne, acne keloidalis nuchae, chloracne, pyoderma faciale, and cysts; c) folliculitis, including, but limited to, scalp folliculitis, spa pool folliculitis, oil folliculitis, pityrosporum folliculitis, and gram negative folliculitis; d) pseudofolliculitis barbae; e) chilblains; f) miliaria (prickly
  • Dermal inflammation results in edema, erythema and tenderness.
  • Dermal inflammation has the advantage of being rapidly induced, easily observed and rapidly measured.
  • Epidermal keratinocytes which respond directly to a irritant because of their superficial location, also, release inflammatory mediators. These mediators can act directly (1) to attract inflammatory cells to the endothehum of the dermal venules or (2) to guide inflammatory cells through the dermis to the site of inflammation after they have passed through the vascular endothehum.
  • mice Increasing concentrations of TPA dissolved in acetone were applied with the aid of a micropipetter onto the right ear of each of the five 6-8 week old, male Swiss Webster mice used in this analysis. Ten microliters were spread evenly onto the inner and outer surfaces using the pipette tip. The mice were then returned to their cages. The contralateral ear was treated only with acetone. After 5.5 hours, the mice were sacrificed and 6 mm punches were taken from each ear and weighed. Edema response was expressed as a percent increase in the treated ear's weight over the untreated ear.
  • the increase in ear weight depends on TPA dose from 0.25 to 1.75 ⁇ g / 20 ⁇ l, reaching a maximum increase of approximately 150%) of the acetone-treated ear.
  • This experiment identified doses between 1.5 - 2.0 ⁇ g / 20 ⁇ l as suitable to use in eliciting edema in future tests of anti-inflammatory agents.
  • Each concentration was applied with the aid of a micropipetter onto the right ear of each of six mice so that 10 ⁇ l of each of the concentrations of the AFC inventive compositions were applied to an inner ear surface and 10 ⁇ l was applied to an outer ear surface of the right ear.
  • the AFC inventive compositions were spread evenly with a pipette tip. Each contralateral ear was treated with only acetone in the same manner. The mice then were returned to their cages. After 5.5 hours, mice were sacrificed and 6 mm punches were taken from each ear and weighed. Edema response was expressed as the percent increase in the treated ear's weight over the untreated (acetone, vehicle only) ear.
  • the ED 50 of the inventive AFC composition was approximately 0.44 mg/20 ⁇ l for TPA-induced edema inhibition.
  • Example 2. AFC inhibits TPA-induced neutrophil infiltration in mice.
  • TPA induces neutrophil infiltration in mice.
  • Acute contact irritants such as TPA can also induce dermal infiltration of neutrophils. This may or may not be independent of the reduction of edema, as: 1) the maximum neutrophil response is delayed relative the maximal edema response; 2) some initants will induce edema independent of neutrophil infiltration; and 3) some of the known anti-inflammatory agents reduce one, but not the other.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2005/020555 2004-06-12 2005-06-13 Topical compositions and methods for epithelial-related conditions Ceased WO2005123103A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN2005800274693A CN101039689B (zh) 2004-06-12 2005-06-13 用于上皮相关病症的局部组合物和方法
CA2579605A CA2579605C (en) 2004-06-12 2005-06-13 Topical compositions and methods for epithelial-related conditions
ES05757465T ES2420516T3 (es) 2004-06-12 2005-06-13 Composiciones tópicas y uso de las mismas para el tratamiento de afecciones relacionadas con el epitelio
DK05757465.9T DK1765376T3 (da) 2004-06-12 2005-06-13 Topiske sammensætninger og anvendelse deraf til behandling af epitel-relaterede tilstande
BRPI0512021-7A BRPI0512021A (pt) 2004-06-12 2005-06-13 composições tópicas e métodos para tratar condições epiteliais correlatas
MXPA06014514A MXPA06014514A (es) 2004-06-12 2005-06-13 Composiciones topicas y metodos para condiciones relacionada con epitelio.
AU2005254035A AU2005254035B2 (en) 2004-06-12 2005-06-13 Topical compositions and methods for epithelial-related conditions
RU2007101243/15A RU2007101243A (ru) 2004-06-12 2005-06-13 Композиции и способы для местного применения для состояний, связанных с эпителием
EP05757465.9A EP1765376B1 (en) 2004-06-12 2005-06-13 Topical compositions and use thereof for the treatment of epithelial-related conditions
JP2007527776A JP4987715B2 (ja) 2004-06-12 2005-06-13 上皮関連状態のための局所用組成物及び方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57909304P 2004-06-12 2004-06-12
US60/579,093 2004-06-12
US65292105P 2005-02-14 2005-02-14
US60/652,921 2005-02-14

Publications (1)

Publication Number Publication Date
WO2005123103A1 true WO2005123103A1 (en) 2005-12-29

Family

ID=35509456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/020555 Ceased WO2005123103A1 (en) 2004-06-12 2005-06-13 Topical compositions and methods for epithelial-related conditions

Country Status (13)

Country Link
EP (1) EP1765376B1 (https=)
JP (1) JP4987715B2 (https=)
KR (1) KR20070061516A (https=)
CN (1) CN101039689B (https=)
AU (1) AU2005254035B2 (https=)
BR (1) BRPI0512021A (https=)
CA (1) CA2579605C (https=)
DK (1) DK1765376T3 (https=)
ES (1) ES2420516T3 (https=)
MX (1) MXPA06014514A (https=)
PT (1) PT1765376E (https=)
RU (1) RU2007101243A (https=)
WO (1) WO2005123103A1 (https=)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899480A4 (en) * 2005-06-13 2009-04-22 Signum Biosciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
EP2389357A4 (en) * 2009-01-20 2013-01-23 Signum Biosciences Inc INFLAMMATORY COMPLEXES
CN104739758A (zh) * 2013-12-30 2015-07-01 天津高科生产力促进有限公司 N-乙酰-l-半胱氨酸含漱液
US9301988B2 (en) 2007-03-30 2016-04-05 Hi-Tech Pharmacal Co., Inc. Method of treatment using a therapeutic agent for intranasal administration
US9669001B2 (en) 2008-12-20 2017-06-06 Convatec Technologies Inc. Antimicrobial composition
US10117904B2 (en) 2009-11-12 2018-11-06 Signum Biosciences, Inc. Use of anti-bacterial agents for the treatment of epithelial-related conditions
US10232047B2 (en) 2011-12-20 2019-03-19 Vyome Biosciences Private Limited Topical oil composition for the treatment of fungal infections
US10493101B2 (en) 2005-12-14 2019-12-03 Convatec Technologies Inc. Antimicrobial composition
EP3497080A4 (en) * 2016-08-08 2020-07-29 Signum Biosciences, Inc. PHARMACEUTICAL FORMULATIONS AND THEIR USE
FR3104943A1 (fr) * 2019-12-19 2021-06-25 L'oreal Lipoaminoacides et leurs utilisations comme actif antipelliculaire
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US12502454B2 (en) 2013-05-15 2025-12-23 Convatec Technologies Inc. Wound dressing comprising an antimicrobial composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2683258C (en) * 2009-10-20 2011-08-09 Asa Bullion Investment Limited Lotion for cleaning human anorectal area
US20160243011A1 (en) * 2012-09-14 2016-08-25 Elizabeth Arden, Inc. Formulations Comprising Idebenone, N-Acetyl-S-Farnesyl-L-Cysteine and Ergothioneine and Uses Thereof
TWI687405B (zh) * 2016-03-16 2020-03-11 慧穎應用生物科技有限公司 一種沉香樹籽萃取物、製備方法及其應用於抗過敏之用途
CN111773212A (zh) * 2020-08-14 2020-10-16 云南中医药大学 一种瑞香素的应用
CN111909069B (zh) * 2020-08-25 2022-04-19 安徽启威生物科技有限公司 一种可降解的季铵盐化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043268A (en) 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
US5705528A (en) * 1993-11-12 1998-01-06 Ramot University Authority For Applied Research & Industrial Development Farnesyl derivatives and pharmaceutical compositions containing them
WO2004087064A2 (en) 2003-03-26 2004-10-14 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849576A (en) * 1964-01-29 1974-11-19 Oreal Process and cosmetic compositions for the treatment of skin and scalp
US6372793B1 (en) * 1999-08-20 2002-04-16 Florida Agricultural & Mechanical University Method for treatment of a neurological disease characterized by impaired neuromodulator function
US20030228688A1 (en) * 2002-05-31 2003-12-11 Isis Pharmaceuticals Inc. Antisense modulation of isoprenylcysteine carboxyl methyltransferase expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043268A (en) 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
US5705528A (en) * 1993-11-12 1998-01-06 Ramot University Authority For Applied Research & Industrial Development Farnesyl derivatives and pharmaceutical compositions containing them
WO2004087064A2 (en) 2003-03-26 2004-10-14 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Harry's Cosmeticology", 1982, LONGMANN SCIENTIFIC & TECHNICAL
See also references of EP1765376A4 *
VOLKER ET AL., METHODS ENZYMOL., vol. 250, 1995, pages 216 - 225

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899480A4 (en) * 2005-06-13 2009-04-22 Signum Biosciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
US10493101B2 (en) 2005-12-14 2019-12-03 Convatec Technologies Inc. Antimicrobial composition
US9301988B2 (en) 2007-03-30 2016-04-05 Hi-Tech Pharmacal Co., Inc. Method of treatment using a therapeutic agent for intranasal administration
US9669001B2 (en) 2008-12-20 2017-06-06 Convatec Technologies Inc. Antimicrobial composition
EP2389357A4 (en) * 2009-01-20 2013-01-23 Signum Biosciences Inc INFLAMMATORY COMPLEXES
US10117904B2 (en) 2009-11-12 2018-11-06 Signum Biosciences, Inc. Use of anti-bacterial agents for the treatment of epithelial-related conditions
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US10232047B2 (en) 2011-12-20 2019-03-19 Vyome Biosciences Private Limited Topical oil composition for the treatment of fungal infections
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US12502454B2 (en) 2013-05-15 2025-12-23 Convatec Technologies Inc. Wound dressing comprising an antimicrobial composition
CN104739758A (zh) * 2013-12-30 2015-07-01 天津高科生产力促进有限公司 N-乙酰-l-半胱氨酸含漱液
EP3497080A4 (en) * 2016-08-08 2020-07-29 Signum Biosciences, Inc. PHARMACEUTICAL FORMULATIONS AND THEIR USE
FR3104943A1 (fr) * 2019-12-19 2021-06-25 L'oreal Lipoaminoacides et leurs utilisations comme actif antipelliculaire

Also Published As

Publication number Publication date
EP1765376B1 (en) 2013-04-10
JP4987715B2 (ja) 2012-07-25
MXPA06014514A (es) 2007-08-07
AU2005254035A1 (en) 2005-12-29
EP1765376A4 (en) 2009-04-22
JP2008502735A (ja) 2008-01-31
PT1765376E (pt) 2013-06-27
CA2579605A1 (en) 2005-12-29
CA2579605C (en) 2013-10-01
EP1765376A1 (en) 2007-03-28
DK1765376T3 (da) 2013-07-01
CN101039689B (zh) 2013-01-30
KR20070061516A (ko) 2007-06-13
AU2005254035B2 (en) 2011-03-24
ES2420516T3 (es) 2013-08-23
RU2007101243A (ru) 2008-07-20
BRPI0512021A (pt) 2008-02-06
CN101039689A (zh) 2007-09-19

Similar Documents

Publication Publication Date Title
US8334413B2 (en) Topical compositions and methods for epithelial-related conditions
CA2579605C (en) Topical compositions and methods for epithelial-related conditions
US7517912B1 (en) Prostaglandin analog compositions and methods to treat epithelial-related conditions
EP2983678A1 (en) Anti-microbial composition
WO2014043230A2 (en) Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof
US20110070296A1 (en) Topical compositions and methods for utilizing peptides containing lipid-modified cysteine-containing peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2579605

Country of ref document: CA

Ref document number: PA/a/2006/014514

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007527776

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 552079

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005757465

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005254035

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077000738

Country of ref document: KR

Ref document number: 147/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007101243

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005254035

Country of ref document: AU

Date of ref document: 20050613

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005254035

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580027469.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005757465

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512021

Country of ref document: BR